Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683746 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
NCT02683746 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 308 participants.
The verdict
NCT02683746, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
Study Summary
This is a phase III, randomized, double-blind, multicenter, parallel group, repeat-dose, study of 26 weeks duration to evaluate the efficacy, safety, tolerability and pharmacodynamic response of albiglutide liquid drug product relative to the commercial lyophilized drug product. The study will specifically evaluate the potential for immunogenicity (example \[e.g.\] incidences of anti-drug antibodies \[ADA\]) and injection site reactions (ISRs). Albiglutide is a novel analogue of glucagon-like peptide-1 (GLP-1) with a sufficiently long half-life to permit once a week injection. Currently, lyophilized albiglutide and the diluent are provided in a dual chamber cartridge (DCC), single-dose pen injector, requiring reconstitution prior to use. A liquid formulation of albiglutide will enable the commercialization of a liquid product in a single dose, ready-to-use prefilled syringe in an auto-injector. The primary hypothesis of this study is to test that liquid drug product will provide glycemic control (as measured by HbA1c change from baseline) non-inferior to lyophilized drug product for a period of 26 weeks of treatment in subjects with T2DM. This study will comprise of 3 study periods : screening (2 weeks), treatment (26 weeks) and for those subjects not entering the extension study a follow-up period (8 weeks). Approximately 300 subjects will be randomized in a 1:1 ratio to either Albiglutide active liquid auto-injector (LAI) plus Placebo lyophilized DCC pen injector (lyophilized DCC PI); or, Albiglutide lyophilized DCC PI plus Placebo LAI.
Interventions
- DRUG Lyophilized albiglutide DCC pen injector
- DRUG Lyophilized albiglutide DCC pen injector matching placebo
- DRUG Albiglutide liquid auto-injector
- DRUG Albiglutide liquid auto-injector matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2016-03-16 |
| Est. Completion | 2017-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683746
The ClinicalTrials.gov registry entry for NCT02683746 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Lyophilized albiglutide DCC pen injector is the first listed.
NCT02683746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683746 about?
NCT02683746 is a clinical study titled "Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus". This is a phase III, randomized, double-blind, multicenter, parallel group, repeat-dose, study of 26 weeks duration to evaluate the efficacy, safety, tolerability and pharmacodynamic response of albiglutide liquid drug product relative to the commercial lyophilized drug product. The study will speci...
What is the current status of trial NCT02683746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2016-03-16. Estimated completion is 2017-05-15.
What interventions are being tested in trial NCT02683746?
The interventions under investigation include: Lyophilized albiglutide DCC pen injector (DRUG), Lyophilized albiglutide DCC pen injector matching placebo (DRUG), Albiglutide liquid auto-injector (DRUG), Albiglutide liquid auto-injector matching placebo (DRUG).
Who is sponsoring clinical trial NCT02683746?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.